Bharat Biotech claims inability to provide vaccines to Delhi, alleges Manish Sisodia; accuses Centre of controlling supply

Supplies of Covaxin in Delhi are over and as a result, around 100 vaccination centres set up in 17 schools have been closed, Sisodia said

Press Trust of India May 12, 2021 14:13:57 IST
Bharat Biotech claims inability to provide vaccines to Delhi, alleges Manish Sisodia; accuses Centre of controlling supply

File image of Delhi deputy chief minister Manish Sisodia. PTI

New Delhi: Deputy Chief Minister Manish Sisodia on Wednesday said Bharat Biotech has informed the Delhi government that it cannot provide "additional" Covaxin doses to the National Capital.

The stock of Covaxin in Delhi has finished and as a result around 100 vaccination centres set up in 17 schools have been closed, he said.

"The Covaxin manufacturer has in a letter said that it can not provide Delhi government vaccines due to unavailability, under the instruction of concerned government official. It means that the Central government is controlling supply of the vaccine," Sisodia said.

The deputy chief minister said Centre should stop the export of vaccines and share the vaccine formulae from the two manufacturers in the country with other companies for mass-scale production.

He also requested the Union government to approve vaccines available in international market for use in India, and to direct states to vaccinate everyone within three months.

Updated Date:

also read

Bharat Biotech set for Phase 4 trials but Phase 3 data still not out; all you need to know
India

Bharat Biotech set for Phase 4 trials but Phase 3 data still not out; all you need to know

A peer review of the jab is expected in two to four months after it was given to scientific journals, Raches Ella Project Lead COVID-19 Vaccines at Bharat Biotech said on Wednesday

Hindutva not a company, it comes from the heart, says Uddhav Thackeray
Politics

Hindutva not a company, it comes from the heart, says Uddhav Thackeray

Speaking on the occasion of Shiv Sena's foundation day, Thackeray said standing on one's own does not mean just fighting elections but fighting for rights.

Bharat Biotech expects peer review of Covaxin's Phase 3 trial data in Q4 2021
India

Bharat Biotech expects peer review of Covaxin's Phase 3 trial data in Q4 2021

Raches Ella, project lead COVID-19 Vaccines at Bharat Biotech said that there were nine publications on Covaxin so far and the efficacy paper on Phase-3 trials would be the tenth one